To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Praesidian doubles up with pharma deal
The mezzanine firm’s second investment in Meta Pharmaceutical Services brings its exposure to $14m.
